Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC

Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC

Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC
RestartResume

Although we've had success with targeted therapies, there is much more to learn as some patients with non-small cell lung cancer develop resistance.

  • Overview

    When a patient with non-small cell lung cancer harboring a molecular driver alteration develops resistance to their therapy, it’s important that we identify what the source of that resistance is, as Dr. Joshua Bauml from the University of Pennsylvania explains.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free